サマリー

ウェアラブル注射器の世界市場は、2023年には43億ドルに達すると予測され、予測期間2023-2035年の年平均成長率は9％と予測されている。

世界人口の増加により、糖尿病、自己免疫疾患、心臓疾患、癌などの慢性疾患が増加している。この課題に対処するため、製薬業界は革新的な戦略を駆使して患者のニーズに焦点を当て、重要な措置を講じている。現在の治療法では、経口または注射による投薬が主流であり、注射の方がより一般的である。しかし、薬剤の注射は、頻繁な投与、潜在的なエラー、汚染リスク、注射針の損傷などのために患者にとって不便であり、治療計画の遵守度やその効果に影響を及ぼす可能性がある。

幸いなことに、薬物送達装置、特に体内注射器のようなウェアラブルなものには目覚ましい進歩がある。これらのデバイスは持続的な効果をもたらし、患者の治療への従順さを向上させる。特に大型のウェアラブル注射器は、持続投与など様々な投与オプションを提供することで、プロセスを簡素化し、アドヒアランスを向上させています。また、針を刺す際の怪我を軽減する安全機能も備えているため、自宅での治療にも適している。

これらのデバイスの人気は、製薬会社や医療機器会社に、AIアルゴリズム、健康モニタリング用モバイルアプリ、リマインダーシステム、薬物送達を確認する信号など、製品にさらなる機能を追加するよう促している。継続的な技術革新により、ウェアラブル注射器の使用は大幅に増加し、今後数年間の市場成長を促進すると予想される。

レポート範囲
 本レポートでは、ウェアラブル注射器市場を調査し、デバイスの種類、使用性、治療分野、主要地域別に分類している。
 市場成長に影響を与える促進要因、制限、機会、課題など様々な要因について分析を行います。
 市場内の潜在的な利点と障害に関する評価を行い、主要企業の競争環境に関する洞察を提供する。
 主要6地域に関する市場セグメントについて収益予測を提供しています。
 ウェアラブルインジェクター市場の調査において正確な調査結果を確実にするために採用した仮定、品質管理対策、体系的なアプローチを網羅し、調査手法の詳細な解明を提示する。
 大容量ウェアラブル注射器市場全体に影響を与える、為替変動、外国為替の影響、景気後退、インフレ測定など、過去の傾向と経済的影響要因の分析。
 ウェアラブル注射器の現状、予想される短期から長期の進化、調査から得られた主要な知見を強調し、簡潔な概要を示す。
 従来の非経口薬物送達デバイスの概要を示し、その進化を促す要因、服薬アドヒアランス向上における重要性、規制上の考慮点、将来の展望を強調している。
 非インスリン薬物送達について、デバイスの状態、タイプ、使いやすさ、投与量、容器、投与経路、技術、接続性、企業状況を網羅する複数のパラメータに基づいて詳細な評価を実施。
 非インスリン薬物送達について、開発状況、デバイスタイプ、使用性、薬剤容器、投与経路、技術、企業ランドスケープを考慮し、デバイスと薬剤の組み合わせについて包括的な評価を行う。
 インスリンウェアラブル注射器については、デバイスの種類、使いやすさ、投与量、容器の容量、糖尿病の種類、制御機能、接続性、これらの注射器を製造する企業の状況など、さまざまなパラメータを詳細に評価。
 ウェアラブル注射器の比較評価は、企業の強み、製品競争力要因、メーカー規模に基づいて行われる。
 詳細なプロフィールを掲載し、企業概要、財務状況（入手可能な場合）、製品ポートフォリオ、最近の開発状況、将来の展望を特集している。
 包括的なプロフィールは、医薬品の仕様、メカニズム、開発状況、投与頻度、販売情報などを詳述している。
 2015年から2023年までのウェアラブル注射器市場における利害関係者間のパートナーシップについて、パートナーシップの種類、関与するプレーヤー、地理的な影響を考慮した詳細なレビューを実施。
 2000年以降の業界における過去の買収活動の検証を行い、利害関係者の潜在的な買収ターゲットを特定する。
 ウェアラブルインジェクターに関連して出願/付与された特許のレビューを実施し、特許の種類、公開年、管轄、プレイヤーの種類、新たな重点分野、主要特許などのパラメータを分析する。
 薬剤の種類、開発段階、適応症、投与頻度、治療法の種類、投与経路に基づいて、ウェアラブル注射器との併用が期待される市販薬およびパイプライン医薬品/治療法に関する洞察を提供する。
 ウェアラブル注射器に関連する完了済み、進行中、計画中の臨床試験について、募集状況、フェーズ、スポンサー、重点領域、治療分野、地理的位置に焦点を当てた包括的な分析を実施。
 2014年から2023年までのウェアラブル注射器企業の資金調達事例をレビューし、資金調達の種類、対象疾患、積極的なプレーヤー、主要投資家、地理的考察による分析を含む。
 ケーススタディでは、ウェアラブル注射器の製造におけるCMOの関与について議論し、様々なデバイスコンポーネントの製造におけるCMOの役割とサプライチェーンへの影響を詳述している。
 主要地域の医療機器承認に関する規制基準を詳細に調査し、世界の主要地域における規制と償還の状況を比較分析している。
 大容量ウェアラブル注射器市場に影響を与える成長要因、潜在的な阻害要因、新たな機会、既存の課題について分析を行っている。
 ウェアラブル注射器の将来の機会について議論を行い、詳細なSWOTフレームワークの中で市場の将来に影響を与えそうなトレンドとパラメータを強調する。

主要市場企業
 CCBio
 CeQur
 デビオテック
 E3D エルカム薬物送達デバイス
 イーライリリー
 Enable Injections
 ゲレスハイマー
 インスレット
 メドトロニック
 メドラムテクノロジーズ
 ファーマセンス
 ロシュ
 ソンチェボズ
 ワイベル CDS
 ウエスト・ファーマシューティカルズ
 ソイルデベロップメント

ページTOPに戻る

目次

1. PREFACE
1.1. Large Volume Wearable Injectors Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics

3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Drug Delivery Devices
5.3. Conventional Parenteral Drug Delivery Devices
5.3.1. Needlestick Injuries
5.3.2. Incidence and Cost Burden
5.3.3. Prevention of Needlestick Injuries
5.3.4. Government Legislations for the Prevention of Needlestick Injuries
5.4. Emergence of Self-Administration Devices
5.4.1. Key Driving Factors
5.4.1.1. Rising Burden of Chronic Diseases
5.4.1.2. Healthcare Cost Savings
5.4.1.3. Need for Immediate Treatment in Emergency Situations
5.4.1.4. Growing Injectable Drugs Market
5.4.1.5. Need for Improving Medication Adherence
5.5. Available Self-Injection Devices
5.5.1. Prefilled Syringes
5.5.2. Pen-Injectors
5.5.3. Needle-Free Injectors
5.5.4. Autoinjectors
5.5.5. Large Volume Wearable Injectors
5.6. Regulatory Considerations
5.6.1. Medical Devices
5.6.2. Drug Device Combination Products
5.7. Future Perspectives
6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors: Overall Market Landscape
6.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape
6.3.1. Analysis by Status of Development
6.3.2. Analysis by Type of Device
6.3.3. Analysis by Usability
6.3.4. Analysis by Type of Dose
6.3.5. Analysis by Type of Drug Container
6.3.6. Analysis by Mode of Drug Filling
6.3.7. Analysis by Container Volume (mL)
6.3.8. Analysis by Route of Administration
6.3.9. Analysis by Mode of Injection
6.3.10. Analysis by Mechanism of Action / Driving Force
6.3.11. Analysis by Type of Technology
6.3.12. Analysis by Availability of Connectivity Feature
6.3.13. Analysis by Type of Compatible Drug
6.3.14. Analysis by Compatibility with High Viscosity Drugs
6.3.15. Analysis by Therapeutic Area
6.4. Large Volume Wearable Injectors for Non-Insulin Drugs: Developer Landscape
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size
6.4.3. Analysis by Location of Headquarters
6.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Non-Insulin Drugs
7. LARGE VOLUME DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Large Volume Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Device
7.2.3. Analysis by Usability
7.2.4. Analysis by Type of Dose
7.2.5. Analysis by Type of Drug Container
7.2.6. Analysis by Mode of Drug Filling
7.2.7. Analysis by Container Volume (mL)
7.2.8. Analysis by Route of Administration
7.2.9. Analysis by Mode of Injection
7.2.10. Analysis by Type of Compatible Drug
7.2.11. Analysis by Mechanism of Action / Driving Force
7.2.12. Analysis by Type of Technology
7.2.13. Analysis by Therapeutic Area
7.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Leading Players: Analysis by Number of Drug Device Combinations for Non-Insulin Drugs
8. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Large Volume Wearable Injectors for Insulin Drugs: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Device
8.2.3. Analysis by Usability
8.2.4. Analysis by Type of Dose
8.2.5. Analysis by Mode of Drug Filling
8.2.6. Analysis by Container Volume (mL)
8.2.7. Analysis by Type of Diabetes
8.2.8. Analysis by Type of Combination Insulin
8.2.9. Analysis by Period of Use (Days)
8.2.10. Analysis by Type of Device Control Feature
8.2.11. Analysis by Availability of Interoperable Device
8.2.12. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
8.2.13. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
8.2.14. Analysis by Type of Automated Insulin Delivery (AID) Feature
8.2.15. Analysis by Availability of Connectivity Feature
8.2.16. Analysis by Waterproof Capabilities

8.3. Large Volume Wearable Injectors for Insulin Drugs: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Insulin Drugs
9. PRODUCT COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions / Key Parameters
9.3. Methodology
9.4. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
9.4.1. Products Developed by Players in North America
9.4.2. Products Developed by Players in Europe
9.4.3. Products Developed by Players in Asia and Middle East and North Africa
9.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations for Non-Insulin Drugs
9.5.1. Products Developed by Players in North America
9.5.2. Products Developed by Players in Europe
9.5.3. Products Developed by Players in Middle East and North Africa
9.6. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
9.6.1. Products Developed by Players in North America
9.6.2. Products Developed by Players in Europe
9.6.3. Products Developed by Players in Asia and Middle East and North Africa
10. LARGE VOLUME WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES
10.1. Chapter Overview
10.2. Key Players Developing Large Volume Wearable Injectors for Non-Insulin Drugs
10.2.1. CCBio
10.2.1.1. Company Overview
10.2.1.2. Product Portfolio
10.2.1.3. Recent Developments and Future Outlook
10.2.2. E3D Elcam Drug Delivery Devices
10.2.2.1. Company Overview
10.2.2.2. Product Portfolio
10.2.2.3. Recent Developments and Future Outlook
10.2.3. Enable Injections
10.2.3.1. Company Overview
10.2.3.2. Product Portfolio
10.2.3.3. Recent Developments and Future Outlook
10.2.4. Gerresheimer
10.2.4.1. Company Overview
10.2.4.2. Financial Information
10.2.4.3. Product Portfolio
10.2.4.4. Recent Developments and Future Outlook
10.2.5. Sonceboz
10.2.5.1. Company Overview
10.2.5.2. Product Portfolio
10.2.5.3. Recent Developments and Future Outlook
10.2.6. Weibel CDS
10.2.6.1. Company Overview
10.2.6.2. Product Portfolio
10.2.6.3. Recent Developments and Future Outlook
10.2.7. West Pharmaceuticals
10.2.7.1. Company Overview
10.2.4.2. Financial Information
10.2.7.3. Product Portfolio
10.2.7.4. Recent Developments and Future Outlook
10.3. Key Players Developing Large Volume Wearable Injectors for Insulin Drugs
10.3.1. CeQur
10.3.1.1. Company Overview
10.3.1.2. Product Portfolio
10.3.1.3. Recent Developments and Future Outlook
10.3.2. Debiotech
10.3.2.1. Company Overview
10.3.2.2. Product Portfolio
10.3.2.3. Recent Developments and Future Outlook
10.3.3. Eli Lilly
10.3.3.1. Company Overview
10.3.3.2. Financial Information
10.3.3.3. Product Portfolio
10.3.3.4. Recent Developments and Future Outlook
10.3.4. Insulet
10.3.4.1. Company Overview
10.3.4.2. Financial Information
10.3.4.3. Product Portfolio
10.3.4.4. Recent Developments and Future Outlook
10.3.5. Medtronic
10.3.5.1. Company Overview
10.3.5.2. Financial Information
10.3.5.3. Product Portfolio
10.3.5.4. Recent Developments and Future Outlook
10.3.6. Medtrum Technology
10.3.6.1. Company Overview
10.3.6.2. Product Portfolio
10.3.6.3. Recent Developments and Future Outlook
10.3.7. PharmaSens
10.3.7.1. Company Overview
10.3.7.2. Product Portfolio
10.3.7.3. Recent Developments and Future Outlook
10.3.8. Roche
10.3.8.1. Company Overview
10.3.8.2. Financial Information
10.3.8.3. Product Portfolio
10.3.8.4. Recent Developments and Future Outlook
10.3.9. SOOIL Development
10.3.9.1. Company Snapshot
10.3.9.2. Product Portfolio
10.3.9.3. Recent Developments and Future Outlook
11. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES
11.1. Chapter Overview
11.2. 3 mL Micropump (Furosemide)
11.3. 3M hMTS (Adalimumab)
11.4. D-mine Pump (Apomorphine)
11.5. FUROSCIX® On-body Infusor (Furosemide)
11.6. Herceptin sc Injection (Herceptin)
11.7. ND0612H Belt Pump (Levodopa / Carbidopa)
11.8. ND0612L Belt Pump (Levodopa / Carbidopa)
11.9. ND0612L Next Generation Patch Pump (Levodopa / Carbidopa)
11.10. ND0701 (Apomorphine)
11.11. ND0901 (Levodopa / Carbidopa)
11.12. Neulasta OnPro On-Body Injector (Neulasta or Pegfilgrastim)
11.13. Pushtronex System (Repatha or Evolocumab)
11.14. SMT-201(Ketorolac)
11.15. SMT-301 (Bupivacaine)
11.16. The LUTREPULSE System (Lutrepulse)
11.17. Trevyent (Treprostinil)
11.18. ULTOMRIS Smart Dose Injector (Ravulizumab)
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Large Volume Wearable Injectors: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Partner
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Device
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Active Players: Analysis by Type of Partnership
12.3.9. Analysis by Geography
12.3.9.1. Local and International Agreements
12.3.9.2. Intercontinental and Intracontinental Agreements
13. KEY ACQUISITION TARGETS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Scoring Criteria and Key Assumptions
13.4. Potential Acquisition Targets: Non-Insulin Drug Delivery Device Developers
13.5. Potential Acquisition Targets: Insulin Drug Delivery Device Developers
13.6. Concluding Remarks
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Large Volume Wearable Injectors: Patent Analysis
14.3.1. Analysis by Type of Patent
14.3.2. Analysis by Patent Publication Year
14.3.3. Analysis by Jurisdiction
14.3.4. Analysis by CPC Symbols
14.3.5. Word Cloud: Emerging Focus Areas
14.3.6. Analysis by Type of Organization
14.3.7 Most Active Players: Analysis by Number of Patents
14.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics
14.5. Large Volume Wearable Injectors: Patent Valuation Analysis
15. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
15.1. Chapter Overview
15.2. Marketed Drugs
15.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
15.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
15.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
15.2.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors
15.3. Clinical stage Drugs
15.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
15.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
15.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
15.3.1.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors
16. CLINICAL TRIAL ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Large Volume Wearable Injectors: Clinical Trial Analysis
16.3.1. Analysis by Trial Recruitment Status
16.3.2. Analysis by Trial Registration Year
16.3.3 Analysis of Enrolled Patent Population by Trial Registration Year
16.3.4. Analysis by Trial Phase
16.3.5. Analysis of Enrolled Patient Population by Trial Phase
16.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
16.3.7. Analysis by Study Design
16.3.8. Analysis by Type of Sponsor / Collaborator
16.3.9. Leading Players: Analysis by Number of Registered Trials
16.3.10. Word Cloud: Key Focus Areas
16.3.11. Analysis by Therapeutic Area
16.3.12. Most Popular Large Volume Wearable Injectors: Analysis by Number of Registered Trials
16.3.13. Analysis by Geography
16.3.14. Analysis by Trial Recruitment Status and Geography
16.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography
17. FUNDING AND INVESTMENT ANALYSIS
17.1. Chapter Overview
17.2. Types of Funding
17.3. Large Volume Wearable Injectors: Funding and Investment Analysis
17.3.1. Analysis by Year of Funding
17.3.2. Analysis of Amount Invested by Year
17.3.3. Analysis by Type of Funding
17.3.4. Analysis by Type of Device
17.3.5. Analysis of Amount Invested by Year and Type of Funding
17.3.6. Analysis of Amount Invested by Type of Device
17.3.7. Analysis by Target Disease Indication
17.3.8. Most Active Players: Analysis by Number of Funding Instances
17.3.9. Most Active Players: Analysis by Amount Invested
17.3.10. Leading Investors: Analysis by Number of Funding Instances
17.3.11. Analysis by Geography
18. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN
18.1. Chapter Overview
18.2. Device Development Supply Chain
18.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
18.4. List of CMOs
18.4.1. Geographical Distribution of CMOs
18.5 Medical Devices Design and Development Service Providers
19. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
19.1. Chapter Overview
19.2. General Regulatory and Reimbursement Guidelines for Medical Devices
19.3. Regulatory and Reimbursement Landscape in North America
19.3.1. The US Scenario
19.3.1.1. Regulatory Authority
19.3.1.2. Review / Approval Process
19.3.1.3. Reimbursement Landscape
19.3.1.3.1. Payer Mix
19.3.1.3.2. Reimbursement Process
19.3.2. The Canadian Scenario
19.3.2.1. Regulatory Authority
19.3.2.2. Review / Approval Process
19.3.2.3. Reimbursement Landscape
19.3.2.3.1. Payer Mix
19.3.2.3.2. Reimbursement Process
19.3.3. The Mexican Scenario
19.3.3.1. Regulatory Authority
19.3.3.2. Review / Approval Process
19.3.3.3. Reimbursement Landscape
19.3.3.3.1. Payer Mix
19.4. Regulatory and Reimbursement Landscape in Europe
19.4.1. Overall Scenario
19.4.1.1. Overall Regulatory Authority
19.4.1.2. Overall Review / Approval Process
19.4.2. The UK Scenario
19.4.2.1. Regulatory Authority
19.4.2.2. Review / Approval Process
19.4.2.3. Reimbursement Landscape
19.4.2.3.1. Payer Mix
19.4.2.3.2. Reimbursement Process
19.4.3. The French Scenario
19.4.3.1. Regulatory Authority
19.4.3.2. Review / Approval Process
19.4.3.3. Reimbursement Landscape
19.4.3.3.1. Payer Mix
19.4.3.3.2. Reimbursement Process
19.4.4. The German Scenario
19.4.4.1. Regulatory Authority
19.4.4.2. Review / Approval Process
19.4.4.3. Reimbursement Landscape
19.4.4.3.1. Payer Mix
19.4.4.3.2. Reimbursement Process
19.4.5. The Italian Scenario
19.4.5.1. Regulatory Authority
19.4.5.2. Review / Approval Process
19.4.5.3. Reimbursement Landscape
19.4.5.3.1. Payer Mix
19.4.5.3.2. Reimbursement Process
19.4.6. The Spanish Scenario
19.4.6.1. Regulatory Authority
19.4.6.2. Review / Approval Process
19.4.6.3. Reimbursement Landscape
19.4.6.3.1. Payer Mix
19.4.6.3.2. Reimbursement Process
19.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
19.5.1. The Australian Scenario
19.5.1.1. Regulatory Authority
19.5.1.2. Review / Approval Process
19.5.1.3. Reimbursement Landscape
19.5.1.3.1. Payer Mix
19.5.1.3.2. Reimbursement Process
19.5.2. The Brazilian Scenario
19.5.2.1. Regulatory Authority
19.5.2.2. Review / Approval Process
19.5.2.3. Reimbursement Landscape
19.5.2.3.1. Payer Mix
19.5.2.3.2. Reimbursement Process
19.5.3. The Chinese Scenario
19.5.3.1. Regulatory Authority
19.5.3.2. Review / Approval Process
19.5.3.3. Reimbursement Landscape
19.5.3.3.1. Payer Mix
19.5.3.3.2. Reimbursement Process
19.5.4. The Indian Scenario
19.5.4.1. Regulatory Authority
19.5.4.2. Review / Approval Process
19.5.4.3. Reimbursement Landscape
19.5.4.3.1. Payer Mix
19.5.5. The Israeli Scenario
19.5.5.1. Regulatory Authority
19.5.5.2. Review / Approval Process
19.5.5.3. Reimbursement Landscape
19.5.5.3.1. Payer Mix
19.5.6. The Japanese Scenario
19.5.6.1. Regulatory Authority
19.5.6.2. Review / Approval Process
19.5.6.3. Reimbursement Landscape
19.5.6.3.1. Payer Mix
19.5.6.3.2. Reimbursement Process
19.5.7. The New Zealand Scenario
19.5.7.1. Regulatory Authority
19.5.7.2. Review / Approval Process
19.5.7.3. Reimbursement Landscape
19.5.7.3.1. Payer Mix
19.5.7.3.2. Reimbursement Process
19.5.8. The Singaporean Scenario
19.5.8.1. Regulatory Authority
19.5.8.2. Review / Approval Process
19.5.8.3. Reimbursement Landscape
19.5.8.3.1. Payer Mix
19.5.8.3.2. Reimbursement Process
19.5.9. The South Korean Scenario
19.5.9.1. Regulatory Authority
19.5.9.2. Review / Approval Process
19.5.9.3. Reimbursement Landscape
19.5.9.3.1. Payer Mix
19.5.9.3.2. Reimbursement Process
19.5.10. The South African Scenario
19.5.10.1. Regulatory Authority
19.5.10.2. Review / Approval Process
19.5.10.3. Reimbursement Landscape
19.5.11. The Taiwanese Scenario
19.5.11.1. Regulatory Authority
19.5.11.2. Review / Approval Process
19.5.11.3. Reimbursement Landscape
19.5.11.3.1. Payer Mix
19.5.11.3.2. Reimbursement Process
19.5.12. The Thailand Scenario
19.5.12.1. Regulatory Authority
19.5.12.2. Review / Approval Process
19.5.12.3. Reimbursement Landscape
19.6. Comparison of Regional Regulatory Environment
19.7. Concluding Remarks
20. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion
21. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Estimates (2023-2035) (By Value)
21.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Value)
21.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Value)
21.3.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Value)
21.3.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035 (By Value)
21.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.1.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.2.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.3.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Value)
21.4. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Volume)
21.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Volume)
21.4.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Volume)
21.4.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (By Volume)
21.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distr